HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen.
Early failures to stavudine/lamivudine/nevirapine used as a generic fixed-dose combination in Mali showed resistance mutations in 50% of cases (mostly M184V and Y181C). No thymidine analogue mutations were seen, suggesting that most nucleoside reverse transcriptase inhibitors could be used in a second-line regimen. This highlights the importance of the accessibility of HIV-RNA assays for monitoring treated patients in resource-poor countries to detect early virological failure in order to preserve future therapeutic options.
Marcelin
Anne-Geneviève
AG
Pitié-Salpêtrière Hospital, Paris, France.
Jarrousse
Bernard
B
Derache
Anne
A
Ba
Madina
M
Dakouo
Marie-Léa
ML
Doumbia
Alioune
A
Haidara
Ibrahima
I
Maïga
Almoustapha
A
Carcelain
Guislaine
G
Peytavin
Gilles
G
Katlama
Christine
C
Calvez
Vincent
V
D000328:Adult; D003906:Developing Countries; D004338:Drug Combinations; D024921:Drug Resistance, Multiple, Viral; D016568:Drugs, Generic; D005260:Female; D019450:Genes, MDR; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1 / Q000235:genetics / Q000502:physiology*; D006801:Humans; D019259:Lamivudine / Q000097:blood / Q000627:therapeutic use; D008297:Male; D008302:Mali; D009154:Mutation; D019829:Nevirapine / Q000097:blood / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D018119:Stavudine / Q000097:blood / Q000627:therapeutic use; D017211:Treatment Failure; D019562:Viral Load
D004338:Drug Combinations; D016568:Drugs, Generic; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D019829:Nevirapine; D018119:Stavudine